Skip to content
Open access

Enhancer-targeted CRISPR-A rescues haploinsufficiency and mutant phenotypes in organoid models of autism.

Nov 2026 · Nature Neuroscience · 0 citations · 66 references
Medicine

Abstract

Autism spectrum disorder (ASD) is a highly heritable condition with diverse clinical presentations. Approximately 15% of the genetic susceptibility of ASD is imparted by de novo haploinsufficient mutations of major effect. We mapped enhancers of two high-confidence autism genes, CHD8 and SCN2A, and used CRISPR-based gene activation targeting enhancers (eCRISPR-A) in human pluripotent stem cell (hPSC)-derived excitatory neurons and cerebral forebrain organoids to correct the effects of haploinsufficiency, taking advantage of the presence of a wild-type allele of each gene and endogenous gene regulation. Here we show that eCRISPR-A induced a sustained increase in CHD8 and SCN2A expression specifically in mutant neurons and cortical organoids, with rescue of gene expression levels and mutation-associated phenotypes, including gene expression and physiology. These data support gene activation via targeting enhancers of haploinsufficient genes as a therapeutic intervention in ASD and other neurodevelopmental disorders.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.